Edwards Lifesciences (EW) Non-Current Assets (2009 - 2026)

Edwards Lifesciences' Non-Current Assets history runs 18 years deep, the most recent figure standing at $7.1 billion for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 4.15% year-over-year to $7.1 billion in Q1 2026; TTM through Mar 2026 was $27.9 billion, a 9.72% increase from a year earlier, with the FY2025 full-year figure at $7.0 billion, up 2.78% from the prior year.
• Non-Current Assets rose to $7.1 billion in Q1 2026 per EW's latest filing, from $7.0 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $7.1 billion in Q1 2026 and bottomed at $5.1 billion in Q3 2022.
• The 5-year median for Non-Current Assets is $5.6 billion (2024), against an average of $5.9 billion.
• Across the five-year window, Non-Current Assets fell 2.35% in 2022 and advanced 27.07% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $5.2 billion in 2022, then increased by 2.52% to $5.3 billion in 2023, then advanced by 27.07% to $6.8 billion in 2024, then rose by 2.78% to $7.0 billion in 2025, then rose by 1.93% to $7.1 billion in 2026.
• Per Business Quant, the three latest EW Non-Current Assets figures stand at $7.1 billion (Q1 2026), $7.0 billion (Q4 2025), and $6.9 billion (Q3 2025).